The National Lipid Association (NLA) and Foundation of the National Lipid Association (FNLA) Urge CMS and Administrator Oz to Include Low-Density Lipoprotein Cholesterol (LDL-C) Measurement in CMS Quality Measurement Programs
To address the ASCVD chronic disease crisis, Christie M. Ballantyne, MD, President of the NLA stated:
There is overwhelming evidence that lowering LDL-C leads to a proportional decrease in ASCVD risk and that LDL-C is a reliable and established measure of atherogenic lipoproteins; however, there is also irrefutable evidence that clinicians are not measuring or managing LDL-C as recommended by the American Heart Association, American College of Cardiology, multisociety guidelines.
Existing guidelines from the American Heart Association, American College of Cardiology, and other leading organizations provide the highest level of evidence support for measuring LDL-C in patients with ASCVD, including:
Adherence to changes in lifestyle and effects of LDL-C lowering medications should be assessed by measurement of fasting lipids and appropriate safety indicators 4 to 12 weeks after statin initiation or dose adjustment and every 3 to 12 months thereafter based on need to assess adherence or safety.[i],[ii]
Recent data shows that only 29.9% of Medicare beneficiaries had LDL-C measured within 90 days of hospital discharge for myocardial infarction,[iii] only 49.9% of patients with ASCVD are on any statin therapy.[iv]
With LDL-C a well-established causal risk factor for ASCVD progression and clear guidance from the leading organizations in the United States, CMS quality measures could play a greater role in increasing LDL-C measurement and management. "Existing measures that consider whether a patient received a prescription for a statin or was dispensed a statin are not consistent with the standard of care, as those measures fail to assess whether the patient is taking their medication or if the medication is working as intended," continued Ballantyne.
"Quality measures can incentivize and prioritize care for many clinicians and patients. Improving existing quality measures to focus on measuring lipids, including LDL-C, will provide the necessary information to clinicians to improve prevention of cardiovascular events and empower patients to make informed decisions about their health," stated James A. Underberg, MD, MNLA, President of the Foundation.
The NLA and Foundation of the NLA welcome any opportunity to work with CMS and Dr. Oz toward helping develop evidence-based updates, quality measures, or other interventions to help stem the ASCVD crisis – with a focus on effective LDL-C measurement and management.
For media inquiries, please contact Brian Hart, Executive Director of the National Lipid Association, at exec@lipid.org.
About the National Lipid Association:The National Lipid Association (NLA) is a nonprofit, multidisciplinary medical society focused on enhancing the science and practice of lipidology and promote optimal cardiometabolic health, representing more than 2,200 members throughout the United States. The NLA is the leader in this field, having published numerous clinical recommendations for lipid management, served as a co-author of the 2018 American Heart Association/American College of Cardiology/Multisociety cholesterol guidelines and 2023 American Heart Association/American College of Cardiology/Multisociety chronic coronary disease guidelines, and serves as the primary educator and advocate for clinical lipidology. Website: www.lipid.org.
About the Foundation of the National Lipid AssociationThe Foundation of the National Lipid Association is a 501(c)(3) nonprofit organization focused on improving the welfare of patients and families affected by cholesterol and triglyceride problems. The Foundation of the National Lipid Association develops and maintains resources for patients, families, and caregivers for common and rare cholesterol and triglyceride disorders to support management of lipid-related health problems that may put patients at risk for a heart attack or stroke. Website: www.learnyourlipids.com.
i Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, Saseen JJ, Smith SC Jr, Sperling L, Virani SS, Yeboah J. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/ APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139:e1082e.ii Virani SS, Newby LK, Arnold SV, Bittner V, Brewer LC, Demeter SH, Dixon DL, Fearon WF, HessB, Johnson HM, Kazi DS, Kolte D, Kumbhani DJ, LoFaso J, Mahtta D, Mark DB, Minissian M, Navar AM, Patel AR, Piano MR, Rodriguez F, Talbot AW, Taqueti VR, Thomas RJ, vanDiepen S, Wiggins B, Williams MS. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease: a report of the AmericanHeart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2023;148:e9–e119. doi: 10.1161/CIR.0000000000001168.iii Nelson, A, Haynes, K, Shambhu, S. et al. High-Intensity Statin Use Among Patients With Atherosclerosis in the U.S. JACC. 2022 May, 79 (18) 1802–1813.https://doi.org/10.1016/j.jacc.2022.02.048.iv Colantonio, L, Wang, Z, Jones, J. et al. Low-Density Lipoprotein Cholesterol Testing Following Myocardial Infarction Hospitalization Among Medicare Beneficiaries. JACC Adv. 2024 Jan, 3 (1). https://doi.org/10.1016/j.jacadv.2023.100753.
View original content to download multimedia:https://www.prnewswire.com/news-releases/the-national-lipid-association-nla-and-foundation-of-the-national-lipid-association-fnla-urge-cms-and-administrator-oz-to-include-low-density-lipoprotein-cholesterol-ldl-c-measurement-in-cms-quality-measurement-programs-302459097.html
SOURCE National Lipid Association
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
12 hours ago
- Forbes
Changes In Prior Approval Coming To Traditional Medicare, Medicare Advantage
There were two major announcements recently regarding prior approval of treatments and services for Medicare beneficiaries. In most medical insurance, many treatments won't be covered unless it is approved first by the insurer. It's been a source of controversy for some time. Original Medicare hasn't required prior authorization of treatments and services, with a few exceptions. For most care, providers and the patient agree on a treatment. After the treatment, paperwork for approval and payment is submitted to Medicare. Medicare recently announced a new model program that will test pre-approval. The voluntary model program will test pre-approval for some services and treatments, according to a recent announcement from the Center for Innovation of the Centers for Medicare and Medicaid Services. The model program is seeking medical providers to volunteer for the program from Jan. 1, 2026 through Dec. 31, 2031. The model will be restricted to New Jersey, Ohio, Oklahoma, Texas, Arizona, and Washington. Providers who volunteer and are accepted will agree to seek prior authorization for 17 items and services, including skin substitutes, deep brain stimulation for Parkinson's Disease, impotence treatment, and arthroscopy for knee osteoarthritis. A provider who volunteers for the program can choose not to seek prior approval for a case. There will be a post-treatment review of the case, and the provider will risk not being paid by Medicare for the treatment. CMS initiated the program and selected the services to be covered because of a series of reports showing waste, fraud or abuse in certain areas. For example, Medicare spent up to $5.8 billion in 2022 on unnecessary or inappropriate services that had no clinical benefit, according to the Medicare Payment Advisory Commission. Under the model, providers will submit the same information they currently submit for payment approval after a service is provided to a beneficiary. The difference is that under the model, the information will be submitted earlier and the provider will wait for approval before performing the services. CMS will select companies to receive and review the prior authorizations. It expects that they will use artificial intelligence and other tools in addition to medical professionals to review the submissions. The companies will be paid based on the extent to which they saved the government money by stopping unnecessary services. CMS said it will manage the program to avoid adverse impact on beneficiaries and providers. There was other news about pre-approval, this time involving Medicare Advantage plans. Pre-approval in Medicare Advantage plans has been controversial recently. There have been a number of recent reports and studies that found the authorization process was delaying treatment or causing patients to abandon treatment plans. Other reports indicated that a high percentage of treatments that initially were denied coverage eventually were approved if the patients or their providers appealed the than 50 major insurers who sponsor many types of insurance plans announced that they will voluntarily streamline prior authorization of treatments and services in all insurance markets, including Medicare Advantage plans. The insurers say they plan to have the new process in place by Jan. 1, 2027.
Business Insider
17 hours ago
- Business Insider
UnitedHealth (UNH) Is About to Report Q2 Earnings on July 29. Here Is What to Expect
UnitedHealth (UNH), one of the prominent players in the health insurance space, is scheduled to announce its second-quarter earnings on July 29. The stock has dropped 43.8% year-to-date, hit by several issues, including the suspension of its guidance, escalating medical costs, and a leadership shakeup that included the sudden departure of its CEO, Andrew Witty. Wall Street analysts expect the company to report earnings per share of $4.48, representing a 34% decrease year-over-year. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Meanwhile, revenues are expected to increase by 13% from the year-ago quarter to $111.5 billion, according to data from the TipRanks Forecast page. It's important to note that UNH has an impressive track record with earnings, having exceeded EPS estimates in eight out of the past nine consecutive quarters. On July 24, UnitedHealth Group (UNH) revealed in an SEC filing that it is under formal investigation by the Department of Justice (DOJ) over its Medicare billing practices. The company said it is cooperating with both civil and criminal probes into whether it improperly raised patient diagnoses to secure higher payments from the government. J.P. Morgan analyst Lisa Gill remains optimistic ahead of UnitedHealth's earnings, viewing the DOJ probe as part of a broader industry trend. She maintained an Overweight rating on the stock, expecting a potential rebound despite near-term uncertainty. Analyst's Views Ahead of UNH's Q2 Earnings Heading into the Q2 print, Deutsche Bank analyst George Hill lowered his price target to $328 from $362 but reiterated a Buy rating. The analyst noted that investor sentiment 'has deteriorated significantly' due to a series of unfavorable news. The top-rated analyst lowered his estimates, citing ongoing concerns around Optum Health, the company's healthcare services unit. Also, Leerink Partners analyst Whit Mayo lowered the price target for UNH stock to $340 from $355 and reiterated a Buy rating. He remains 'cautiously optimistic' about the stock heading into Q2 earnings, given the challenging backdrop. Options Traders Anticipate a Large Move Using TipRanks' Options tool, we can see what options traders are expecting from the stock immediately after its earnings report. The expected earnings move is determined by calculating the at-the-money straddle of the options closest to expiration after the earnings announcement. If this sounds complicated, don't worry; the Options tool does this for you. Indeed, it currently says that move in either direction. Is UNH a Good Buy Now? Turning to Wall Street, UNH stock has a Moderate Buy consensus rating based on 18 Buys, five Holds, and one Sell assigned in the last three months. At $348.12, the average UnitedHealth stock price target implies a 23.86% upside potential.
Associated Press
21 hours ago
- Associated Press
Major Health Insurers Slash Prior Authorization Requirements, Transforming the PA Technology Landscape
Black Book Research identifies Cohere Health, Innovaccer, and Waystar among leading vendors rapidly adapting to new industry rules. NEW YORK CITY, NY / ACCESS Newswire / July 26, 2025 / U.S. healthcare is undergoing a pivotal shift as major insurers-led by UnitedHealthcare and Humana-begin to significantly reduce or eliminate prior authorization (PA) requirements for hundreds of routine procedures. Accelerated by federal policy, provider frustration, and consumer demands for timely access to care, these sweeping changes signal a new era in PA technology and operations, according to a July 2025 flash survey conducted by Black Book Research. Industry Drivers: Regulatory Action Meets Provider and Consumer Pressure Insurers covering over 250 million Americans have committed to streamlining or removing PA burdens by the end of 2026. This is partly driven by the Centers for Medicare & Medicaid Services (CMS), which is launching a pilot program in six states in January 2026 requiring faster, more transparent prior authorizations for select Medicare services. CMS has also announced national response time standards for Medicare Advantage plans, further intensifying the need for automation and interoperability in PA processes. Key Survey Insights from the Field Black Book Research's flash survey compiled viewpoints from: 24 IT leaders representing the top 10 PA vendors; 108 managed care and health plan IT and operational decision-makers; 142 healthcare providers and administrative leaders; and 100 healthcare consumers with recent PA experiences. Notable Findings: 84% of managed care executives support reducing PA requirements 96% of healthcare providers report improved workflows and lower administrative burdens 99% of consumers favor eliminating PA for routine care; 83% say they've experienced harmful care delays 67% of health plans expect to reevaluate or end contracts with existing PA vendors by 2026 Additional Observations: 90% of providers foresee broad adoption of interoperable PA tools by 2027 94% of payers plan substantial investment in AI-based PA platforms 100% of consumers prefer providers with automated and transparent PA processes 96% of PA vendor executives acknowledge their current solutions require modernization within two years __________ Vendors Rapidly Adapting and Leading the Innovation Curve: Client Top KPI Scores Black Book highlights the top-performing vendors already making critical advancements to align with industry shifts: Cohere Health - Excels in AI-based automation, payer-provider integration, and CMS-aligned interoperability Innovaccer - Offers strong EHR integration and regulatory compliance dashboards for PA workflows Waystar - Enhancing its Auth Accelerate platform for real-time eligibility checks and exception handling ScribeRunner - Developing dynamic auto-approval rulesets and real-time tracking modules CoverMyMeds - Expanding AI-powered real-time authorizations for both pharmacy and medical benefits Change Healthcare - Transitioning legacy infrastructure with modular FHIR APIs for automated decision-making Availity - Driving advanced API adoption and digital submission channels PriorAuthNow (Rhyme) - Connecting providers and payers through real-time electronic submission with limited manual effort Black Book's Q1-Q2 client satisfaction rankings show these vendors excelled across 18 qualitative KPIs for PA technology. Cohere Health earned the highest overall honors, with MCG Health, eviCore Healthcare, Agadia, Infinx, and Availity also receiving good marks. Onyx led in FHIR-based PA platform innovation. Detailed competitive intelligence reports are available in the Black Book research store. __________ Vendors Facing Existential Threats in the New Era Not all companies are poised for success. Several previously top-rated PA vendors now face considerable risk due to outdated systems and slow adaptability: eviCore Healthcare - Still dependent on manual review processes, with limited AI capabilities HealthHelp (WNS) - Lagging behind in interoperability and modern payer integration PriorAuthNow (Rhyme) - Despite innovation efforts, struggles with scalable real-time API integration threaten its long-term viability _________ Looking Ahead: A Positive Outlook for Adaptive Vendors While legacy vendors must evolve rapidly or risk market exit, the broader outlook for PA tech is optimistic. Companies investing in automated, intelligent, and interoperable systems are well-positioned to thrive. 'The future of prior authorization is transparent, automated, and fully integrated into clinical workflows,' said Doug Brown, Founder of Black Book Research. 'Vendors delivering real-time, AI-powered solutions will define the next generation of care access efficiency for providers, payers, and patients alike.' About Black Book Research Black Book Research is a leading healthcare IT research firm known for its independent, vendor-agnostic approach. Over the past 15 years, Black Book has collected over 3 million survey responses from nearly 500,000 healthcare professionals. The firm's flash surveys and long-form evaluations provide real-time, unbiased insights that support strategic decision-making across the healthcare ecosystem. Visit or contact [email protected] for full survey results and vendor-specific performance details. Contact InformationPress Office 8008637590 SOURCE: Black Book Research press release
